Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241
Debt
Debt-to-Equity Ratio0.74
Current Ratio2.26
Quick Ratio2.26
Price-To-Earnings
Trailing P/E Ratio-2.70
Forward P/E Ratio-3.01
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book5.24
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-28,940,000.00
Net MarginsN/A
Return on Equity-198.09%
Return on Assets-89.32%
Miscellaneous
Employees25
Outstanding Shares26,250,000
Market Cap$90.57 million
Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions
What is Axsome Therapeutics' stock symbol?
Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
How were Axsome Therapeutics' earnings last quarter?
Axsome Therapeutics Inc (NASDAQ:AXSM) released its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). View Axsome Therapeutics' Earnings History.
When is Axsome Therapeutics' next earnings date?
What price target have analysts set for AXSM?
3 Wall Street analysts have issued 1-year target prices for Axsome Therapeutics' shares. Their forecasts range from $10.00 to $16.00. On average, they anticipate Axsome Therapeutics' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 275.7% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.
What is the consensus analysts' recommendation for Axsome Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.
Who are some of Axsome Therapeutics' key competitors?
Some companies that are related to Axsome Therapeutics include Synlogic (SYBX), Clementia Pharmaceuticals (CMTA), American Brivision (Holding) (ABVC), Selecta Biosciences (SELB), Concert Pharmaceuticals (CNCE), Corium International (CORI), Geron (GERN), Tocagen (TOCA), Seres Therapeutics (MCRB), Neptune Wellness Solutions (NEPT), Sienna Biopharmaceuticals (SNNA), Paratek Pharmaceuticals (PRTK), Unum Therapeutics (UMRX), MEI Pharma (MEIP) and Innate Pharma (IPHYF).
Who are Axsome Therapeutics' key executives?
Axsome Therapeutics' management team includes the folowing people:
- Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 50)
- Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 43)
- Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 35)
- Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 43)
- Joseph Debrah-Afful, Director of Fin.
When did Axsome Therapeutics IPO?
(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
How do I buy shares of Axsome Therapeutics?
Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axsome Therapeutics' stock price today?
One share of AXSM stock can currently be purchased for approximately $3.46.
How big of a company is Axsome Therapeutics?
Axsome Therapeutics has a market capitalization of $90.57 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe.
What is Axsome Therapeutics' official website?
How can I contact Axsome Therapeutics?
Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.
MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
